BioSpace News Archive

Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics)

Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced today that Theodore (Ted) A. Asbhurn, M.D., Ph.D., President and Chief Executive Officer, will present at the upcoming Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 3:50 pm GMT (10:50 am ET). A live webcast of the presentation will be available under the Investors

Epsolay ® PDUFA goal date set for April 26, 2021 Twyneo ® New Drug Application submitted to the U.S. FDA Top-line generic product revenue of $2.1 million in 3Q 2020 In October 2020 , signed an 11th generic product collaboration agreement with Perrigo

- Enrollment Complete in the Phase 3 DeFi Trial of Nirogacestat in Adult Patients with Desmoid Tumors - - Clinical Collaborations Signed with Janssen, Pfizer and Precision Biosciences to Evaluate Nirogacestat in Combination with BCMA-Directed Therapies Across Modalities for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma - - Entered into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center

Acquisition of Handl Therapeutics BV augments UCB’s existing early gene therapy pipeline with two research programs, a proprietary adeno-associated virus (AAV) capsid technology platform and capabilities

Q3/2020 net revenues of approximately $21 million, with gross profit of $10.6 million, or approximately 51%, up from $6.7 million and approximately 32% in Q2/2020

Valeo Pharma Inc., a Canadian pharmaceutical company, announced that it has recently received a Notice of Compliance from Health Canada granting market authorization for Amikacin, an antibiotic used within the hospital setting.

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2020 . Leap Third Quarter Highlights: First patient dosed in Phase 2a study of Leap’s anti-Dickkopf-1 (DKK1) antibo

Strong pipeline progress amid challenging COVID-19 environment Oral presentation of MAD1 results at upcoming 2020 ASH Virtual Annual Meeting from the randomized, placebo-controlled multi-center Phase 1 trial evaluating FT-4202 in people with sickle cell disease MAD2 cohort of the Phase 1 trial now enrolling with 600 mg dose

- Submitted BLA for lead program, Lonca, for treatment of relapsed or refractory DLBCL on September 21, 2020 - Commercial launch activities on track for potential U.S. launch of Lonca in mid-2021 - Initiated Phase 3 confirmatory trial of Lonca in combination with rituximab in second-line DLBCL - Strong balance sheet with $494 million in cash and cash equivalents as of September 30, 2020